COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said its insulin degludec had shown 43 percent lower rates of night-time low blood sugar levels than glargine from rival drugmaker Sanofi.
Novo Nordisk said in a statement the data was presented on Tuesday at the Annual Meeting of the European Association for the Study of Diabetes (EASD).
The data had been collected in a two-year phase IIIa study, Novo Nordisk said.
(Reporting by Mette Fraende)
Advertisement
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
0 comments
- Get Livefyre
- FAQ
Newest | Oldest
